Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1955)
All Articles published online
|
Feb 14, 2006 (publication date) through May 10, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn’s disease: Need for HBV-screening? World J Gastroenterol 2006; 12(6): 974-976 [PMID: 16521231 DOI: 10.3748/wjg.v12.i6.974] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i6/974.htm |
| Number | Citing Articles |
| 1 |
R. Cavallo. The laboratory of clinical virology in monitoring patients undergoing monoclonal antibody therapy. Clinical Microbiology and Infection 2011; 17(12): 1781 doi: 10.1111/j.1469-0691.2011.03678.x
|
| 2 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, P. Daffra, J.A. De Paula, J. Etchevers, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.M. Marroquín de la Garza, R. Monreal Robles, J.L. Rocha, F. Steinwurz, R. Vázquez-Frías, G. Veitia, C. Zaltman. Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). Revista de Gastroenterología de México 2017; 82(2): 134 doi: 10.1016/j.rgmx.2016.07.005
|
| 3 |
Luis Vida Pérez, Federico Gómez Camacho, Valle García Sánchez, Eva M.a Iglesias Flores, Laura Castillo Molina, Antonio Cerezo Ruiz, Luis Casáis Juanena, Juan Francisco De Dios Vega. Eficacia de la vacuna contra el virus de la hepatitis B en pacientes con enfermedad inflamatoria intestinal. Medicina Clínica 2009; 132(9): 331 doi: 10.1016/j.medcli.2008.07.013
|
| 4 |
Anna Felis-Giemza, Marzena Olesińska, Katarzyna Świerkocka, Ewa Więsik-Szewczyk, Ewa Haładyj. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatology International 2015; 35(3): 385 doi: 10.1007/s00296-014-3195-8
|
| 5 |
Matthew B. Carroll, Michael A. Forgione. Use of tumor necrosis factor α inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clinical Rheumatology 2010; 29(9): 1021 doi: 10.1007/s10067-010-1523-2
|
| 6 |
I. Marie, E. Guglielmino. Infections opportunistes non tuberculeuses au cours des traitements par les anti-TNFα. La Revue de Médecine Interne 2010; 31(5): 353 doi: 10.1016/j.revmed.2009.04.010
|
| 7 |
J. CARBONE, V. GONZALEZ‐LARA, E. SARMIENTO, C. CHEAN, J. L. PEREZ, I. MARIN, J. J. RODRÍGUEZ‐MOLINA, J. GIL, E. FERNÁNDEZ‐CRUZ. Humoral and Cellular Monitoring to Predict the Development of Infection in Crohn's Disease Patients Beginning Treatment with Infliximab. Annals of the New York Academy of Sciences 2007; 1107(1): 346 doi: 10.1196/annals.1381.036
|
| 8 |
Dimitrios Vassilopoulos, Leonard H Calabrese. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Current Opinion in Rheumatology 2007; 19(6): 619 doi: 10.1097/BOR.0b013e3282f05b63
|
| 9 |
J. P. Gisbert, M. Chaparro, M. Esteve. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011; 33(6): 619 doi: 10.1111/j.1365-2036.2010.04570.x
|
| 10 |
Clodoveo Ferri, Marcello Govoni, Leonard Calabrese. The A, B, Cs of viral hepatitis in the biologic era. Current Opinion in Rheumatology 2010; 22(4): 443 doi: 10.1097/BOR.0b013e328338f6df
|
| 11 |
YUN JUNG KIM, SANG-CHEOL BAE, YOON-KYOUNG SUNG, TAE-HWAN KIM, JAE-BUM JUN, DAE-HYUN YOO, TAE YEOB KIM, JOO HYUN SOHN, HYE-SOON LEE. Possible Reactivation of Potential Hepatitis B Virus Occult Infection by Tumor Necrosis Factor-α Blocker in the Treatment of Rheumatic Diseases. The Journal of Rheumatology 2010; 37(2): 346 doi: 10.3899/jrheum.090436
|
| 12 |
Gülay Okay, Elmas Biberci Keskin, Yasemin Akkoyunlu, Sibel Bolukcu, Ayse Betül Uslu, Meliha Meric Koc. Evaluation of hepatitis B vaccine efficacy and factors affecting vaccine nonresponse in patients receiving anti-tumor necrosis factor agents. European Journal of Gastroenterology & Hepatology 2021; 33(8): 1091 doi: 10.1097/MEG.0000000000001849
|
| 13 |
Cristina González-Artacho, María José Rodríguez Sicilia, Carlos Alegría-Motte, María Gómez García. Evolución de la hepatitis crónica B y C en pacientes con enfermedad inflamatoria intestinal tratada con inmunosupresores y antifactor de necrosis tumoral (anti-TNF). Gastroenterología y Hepatología 2014; 37(1): 23 doi: 10.1016/j.gastrohep.2013.07.008
|
| 14 |
Sophia Li, Primal P. Kaur, Virginia Chan, Steven Berney. Use of tumor necrosis factor-α (TNF-α) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clinical Rheumatology 2009; 28(7): 787 doi: 10.1007/s10067-009-1149-4
|
| 15 |
Sebastian Bernardo, Laurel Geraghty, Ahuva Freilich, Michael Pan, Mark Lebwohl. Frequency of Monotherapy versus Combination Therapy in Reported Cases of Infections Occurring in the Setting of Biologic Agents. Psoriasis Forum 2013; (1): 2 doi: 10.1177/247553031319a00101
|
| 16 |
Jean-Baptiste Chevaux, Abdelbasset Nani, Abderrahim Oussalah, Véronique Venard, Mouni Bensenane, Arthur Belle, Jean-Louis Gueant, Marc-André Bigard, Jean-Pierre Bronowicki, Laurent Peyrin-Biroulet. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflammatory Bowel Diseases 2010; 16(6): 916 doi: 10.1002/ibd.21147
|
| 17 |
Grigorios T. Sakellariou, Ioannis Chatzigiannis. Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clinical Rheumatology 2007; 26(6): 950 doi: 10.1007/s10067-006-0392-1
|
| 18 |
J.-B. Chevaux, M.-A. Bigard, M. Bensenane, A. Oussalah, S. Jarlot, A. Belle, A. Nani, J.-P. Bronowicki, L. Peyrin-Biroulet. Maladies inflammatoires chroniques intestinales et hépatites B et C. Gastroentérologie Clinique et Biologique 2009; 33(12): e1 doi: 10.1016/j.gcb.2009.09.001
|
| 19 |
Konstantinos H. Katsanos, Vasileios E. Tsianos, Christos D. Zois, Heleni Zioga, Ioannis Vagias, Eleftheria Zervou, Dimitrios K. Christodoulou, Epameinondas V. Tsianos. Inflammatory bowel disease and hepatitis B and C in Western Balkans: A referral centre study and review of the literature. Journal of Crohn's and Colitis 2010; 4(4): 450 doi: 10.1016/j.crohns.2010.03.001
|
| 20 |
Dustin G. James, Christian D. Stone, Hanlin L. Wang, William F. Stenson. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases 2006; 12(7): 573 doi: 10.1097/01.MIB.0000225333.83861.16
|
| 21 |
Hala H. Mansour, Ayman E. Eskander, Sara M. Osman, Normeen H. Rady. Incidence of Low Seroimmunity to Hepatitis B Virus in Children with Inflammatory Bowel Disease: A Single Center Experience. Pediatric Gastroenterology, Hepatology & Nutrition 2024; 27(2): 104 doi: 10.5223/pghn.2024.27.2.104
|
| 22 |
M. J. SHALE, C. H. SEOW, C. S. COFFIN, G. G. KAPLAN, R. PANACCIONE, S. GHOSH. Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2010; 31(1): 20 doi: 10.1111/j.1365-2036.2009.04112.x
|
| 23 |
W. Miehsler, G. Novacek, H. Wenzl, H. Vogelsang, P. Knoflach, A. Kaser, C. Dejaco, W. Petritsch, M. Kapitan, H. Maier, W. Graninger, H. Tilg, W. Reinisch. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. Journal of Crohn's and Colitis 2010; 4(3): 221 doi: 10.1016/j.crohns.2009.12.001
|
| 24 |
Mohammad Shehab, Ranim Almatar, Rawan Almohammad, Ahmad Alfadhli. Adherence to Recommended Immunization Schedules in Patients with Inflammatory Bowel Disease on Biologics and Small Molecule Therapies. Gastroenterology Insights 2023; 14(3): 383 doi: 10.3390/gastroent14030028
|
| 25 |
Jeroen N. Stoop, Andrea M. Woltman, Paula J. Biesta, Johannes G. Kusters, Ernst J. Kuipers, Harry L.A. Janssen, Renate G. van der Molen. Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus–specific immune response. Hepatology 2007; 46(3): 699 doi: 10.1002/hep.21761
|
| 26 |
Raquel Rivera Díaz, Francisco Vanaclocha Sebastián. Hígado y psoriasis. Piel 2011; 26(10): 498 doi: 10.1016/j.piel.2011.03.019
|
| 27 |
Waqqas Afif, Edward V. Loftus. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009; 38(4): 691 doi: 10.1016/j.gtc.2009.07.005
|
| 28 |
Sebastian Strobel, Maria T. Abreu. Biologic Therapy in Inflammatory Bowel Disease—A Gastrointestinal Perspective. Seminars in Colon and Rectal Surgery 2012; 23(2): 81 doi: 10.1053/j.scrs.2012.02.007
|
| 29 |
R. Navarro, E. Vilarrasa, P. Herranz, L. Puig, X. Bordas, J.M. Carrascosa, R. Taberner, M. Ferrán, M. García-Bustinduy, A. Romero-Maté, R. Pedragosa, A. García-Diez, E. Daudén. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. British Journal of Dermatology 2013; 168(3): 609 doi: 10.1111/bjd.12045
|
| 30 |
Keisuke Ojiro, Makoto Naganuma, Hirotoshi Ebinuma, Hiroyoshi Kunimoto, Shinichiro Tada, Haruhiko Ogata, Yasushi Iwao, Hidetsugu Saito, Toshifumi Hibi. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. Journal of Gastroenterology 2008; 43(5): 397 doi: 10.1007/s00535-008-2165-x
|
| 31 |
R. Caporali, F. Bobbio‐Pallavicini, F. Atzeni, G. Sakellariou, M. Caprioli, C. Montecucco, P. Sarzi‐Puttini. Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care & Research 2010; 62(6): 749 doi: 10.1002/acr.20130
|
| 32 |
SOO-JIN CHUNG, JA KYUNG KIM, MIN-CHAN PARK, YONG-BEOM PARK, SOO-KON LEE. Reactivation of Hepatitis B Viral Infection in Inactive HBsAg Carriers Following Anti-Tumor Necrosis Factor-α Therapy. The Journal of Rheumatology 2009; 36(11): 2416 doi: 10.3899/jrheum.081324
|
| 33 |
J.F. Rahier, S. Ben-Horin, Y. Chowers, C. Conlon, P. De Munter, G. D'Haens, E. Domènech, R. Eliakim, A. Eser, J. Frater, M. Gassull, M. Giladi, A. Kaser, M. Lémann, T. Moreels, A. Moschen, R. Pollok, W. Reinisch, M. Schunter, E.F. Stange, H. Tilg, G. Van Assche, N. Viget, B. Vucelic, A. Walsh, G. Weiss, Y. Yazdanpanah, Y. Zabana, S.P.L. Travis, J.F. Colombel. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn's and Colitis 2009; 3(2): 47 doi: 10.1016/j.crohns.2009.02.010
|
| 34 |
|
| 35 |
Armin Finkenstedt, Karin Nachbaur, Heinz Zoller, Michael Joannidis, Johann Pratschke, Ivo W. Graziadei, Wolfgang Vogel. Acute-on-chronic liver failure: Excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transplantation 2013; 19(8): 879 doi: 10.1002/lt.23678
|
| 36 |
Francesco Vitale, Fabio Tramuto, Ambrogio Orlando, Giovanni Vizzini, Valentina Meli, Giuseppe Cerame, Walter Mazzucco, Roberto Virdone, Ugo Palazzo, Maria Rosaria Villafrate, Alessandro Tagger, Nino Romano. Can the serological status of “anti‐HBc alone” be considered a sentinel marker for detection of “occult” HBV infection?. Journal of Medical Virology 2008; 80(4): 577 doi: 10.1002/jmv.21121
|
| 37 |
Salvatore Madonia, Ambrogio Orlando, Daniela Scimeca, Mirko Olivo, Francesca Rossi, Mario Cottone. Occult Hepatitis B and Infliximab-induced HBV Reactivation. Inflammatory Bowel Diseases 2007; 13(4): 508 doi: 10.1002/ibd.20035
|
| 38 |
Balakrishnan S. Ramakrishna, Govind K. Makharia, Philip Abraham, Uday C. Ghoshal, Venkataraman Jayanthi, Brij Kishore Agarwal, Vineet Ahuja, Deepak K. Bhasin, Shobna J. Bhatia, Gourdas Choudhuri, Sunil Dadhich, Devendra C. Desai, Gopal Krishna Dhali, Bhaba Dev Goswami, Sanjeev K. Issar, Ajay K. Jain, Rakesh Kochhar, Ajay Kumar, Goundappa Loganathan, Sri Prakash Misra, C. Ganesh Pai, Sujoy Pal, Anna Pulimood, Amarender S. Puri, Ganesh N. Ramesh, Gautam Ray, Shivaram P. Singh, Ajit Sood, Manu Tandan. Indian Society of Gastroenterology consensus on ulcerative colitis. Indian Journal of Gastroenterology 2012; 31(6): 307 doi: 10.1007/s12664-012-0259-0
|
| 39 |
Justine Mill, Ian C Lawrance. Preventing infective complications in inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(29): 9691-9698 doi: 10.3748/wjg.v20.i29.9691
|
| 40 |
Abhishek Watts, William E. Bennett, Jean P. Molleston, Sandeep K. Gupta, Joseph M. Croffie, Shamaila Waseem, Brian A. McFerron, Steven J. Steiner, Sanjay Kumar, Charles P. Vanderpool, Emily C. Hon, Molly A. Bozic, Girish C. Subbarao, Marian D. Pfefferkorn. Incidence of Low Seroimmunity to Hepatitis B Virus in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2017; 65(5): 551 doi: 10.1097/MPG.0000000000001580
|
| 41 |
Carla S. Coffin, Hughie F. Fraser, Remo Panaccione, Subrata Ghosh. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflammatory Bowel Diseases 2011; 17(1): 479 doi: 10.1002/ibd.21336
|
| 42 |
|
| 43 |
J P Gisbert, J R Villagrasa, A Rodríguez-Nogueiras, M Chaparro. Efficacy of Hepatitis B Vaccination and Revaccination and Factors Impacting on Response in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology 2012; 107(10): 1460 doi: 10.1038/ajg.2012.79
|
| 44 |
Francisco Colina, Aída Molero, Begoña Casís, Pilar Martínez-Montiel. Infliximab-Related Hepatitis: A Case Study and Literature Review. Digestive Diseases and Sciences 2013; 58(11): 3362 doi: 10.1007/s10620-013-2698-6
|
| 45 |
Mary Patricia Pauly, Lue-Yen Tucker, Jean-Luc Szpakowski, Joanna B. Ready, David Baer, Jessica Hwang, Anna S.-F. Lok. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology 2018; 16(12): 1964 doi: 10.1016/j.cgh.2018.04.033
|
| 46 |
Roberto Pérez-Alvarez, Cándido Díaz-Lagares, Francisco García-Hernández, Leopoldo Lopez-Roses, Pilar Brito-Zerón, Marta Pérez-de-Lis, Soledad Retamozo, Albert Bové, Xavier Bosch, Jose-Maria Sanchez-Tapias, Xavier Forns, Manuel Ramos-Casals. Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. Medicine 2011; 90(6): 359 doi: 10.1097/MD.0b013e3182380a76
|
| 47 |
Waqqas Afif, Edward V. Loftus. Safety Profile of IBD Therapeutics: Infectious Risks. Medical Clinics of North America 2010; 94(1): 115 doi: 10.1016/j.mcna.2009.08.016
|
| 48 |
Francesca Nacci, Marco Matucci-Cerinic. Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era. Best Practice & Research Clinical Rheumatology 2011; 25(3): 375 doi: 10.1016/j.berh.2011.06.001
|
| 49 |
Elena Toscano, Judit Cotta, Mercedes Robles, Ma Isabel Lucena, Raúl J. Andrade. Toxicidad hepática inducida por los nuevos fármacos inmunosupresores. Gastroenterología y Hepatología 2010; 33(1): 54 doi: 10.1016/j.gastrohep.2009.07.003
|
| 50 |
Lesley Ann Saketkoo, Luis R. Espinoza. Impact of Biologic Agents on Infectious Diseases. Infectious Disease Clinics of North America 2006; 20(4): 931 doi: 10.1016/j.idc.2006.09.001
|
| 51 |
Mauro Viganò, Elisabetta Degasperi, Alessio Aghemo, Pietro Lampertico, Massimo Colombo. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opinion on Biological Therapy 2012; 12(2): 193 doi: 10.1517/14712598.2012.646986
|
| 52 |
STEFANIA ZINGARELLI, MICOL FRASSI, CHIARA BAZZANI, MIRKO SCARSI, MASSIMO PUOTI, PAOLO AIRÒ. Use of Tumor Necrosis Factor-α-blocking Agents in Hepatitis B Virus-positive Patients: Reports of 3 Cases and Review of the Literature. The Journal of Rheumatology 2009; 36(6): 1188 doi: 10.3899/jrheum.081246
|
| 53 |
|
| 54 |
|
| 55 |
A. Orlando, F. Mocciaro, G. Civitavecchia, D. Scimeca, M. Cottone. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008; 40: S236 doi: 10.1016/S1590-8658(08)60532-0
|
| 56 |
F. Morisco, F. Castiglione, A. Rispo, T. Stroffolini, S. Sansone, R. Vitale, M. Guarino, L. Biancone, A. Caruso, R. D'Inca, R. Marmo, A. Orlando, G. Riegler, L. Donnarumma, S. Camera, F. Zorzi, S. Renna, V. Bove, G. Tontini, M. Vecchi, N. Caporaso. Effect of immunosuppressive therapy on patients with inflammatory bowel diseases and hepatitis B or C virus infection. Journal of Viral Hepatitis 2013; 20(3): 200 doi: 10.1111/j.1365-2893.2012.01643.x
|
| 57 |
Lise Lotte Gluud, Jørgen Rask‐Madsen. Pharmaceutical Sciences Encyclopedia. 2010; : 1 doi: 10.1002/9780470571224.pse221
|
| 58 |
Mariantonietta Pisaturo, Giovanni Di Caprio, Federica Calò, Federica Portunato, Salvatore Martini, Nicola Coppola. Management of HBV reactivation in non-oncological patients. Expert Review of Anti-infective Therapy 2018; 16(8): 611 doi: 10.1080/14787210.2018.1505501
|
| 59 |
Brijen Shah, Lloyd Mayer. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Review of Clinical Immunology 2010; 6(4): 607 doi: 10.1586/eci.10.45
|
| 60 |
Manuel Ramos-Casals. Are TNF blockers safe for patients with hepatitis B virus infection?. Nature Reviews Rheumatology 2010; 6(11): 618 doi: 10.1038/nrrheum.2010.156
|
| 61 |
Yolanda Faia Manhães Tolentino, Homero Soares Fogaça, Cyrla Zaltman, Lia Laura Lewis Ximenes, Henrique Sérgio Moraes Coelho. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho university hospital. World Journal of Gastroenterology 2008; 14(20): 3201-3206 doi: 10.3748/wjg.14.3201
|
| 62 |
J.K. Yamamoto-Furusho, F. Bosques-Padilla, P. Daffra, J.A. De Paula, J. Etchevers, M.T. Galiano, P. Ibañez, F. Juliao, P.G. Kotze, J.M. Marroquín de la Garza, R. Monreal Robles, J.L. Rocha, F. Steinwurz, R. Vázquez-Frías, G. Veitia, C. Zaltman. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn's and Colitis Organisation (PANCCO) (Second part). Revista de Gastroenterología de México (English Edition) 2017; 82(2): 134 doi: 10.1016/j.rgmxen.2016.07.004
|
| 63 |
X. Bordas, S. Martín-Sala. Etanercept e infección crónica por los virus de la hepatitis C y B. Actas Dermo-Sifiliográficas 2010; 101: 82 doi: 10.1016/S0001-7310(10)70014-4
|
| 64 |
Bruce Strober, Emily Berger, Jennifer Cather, David Cohen, Jeffrey J. Crowley, Kenneth B. Gordon, Alice Gottlieb, Elizabeth J. Horn, Arthur F. Kavanaugh, Neal J. Korman, Gerald G. Krueger, Craig L. Leonardi, Alan Menter, Sergio Schwartzman, Jeffrey M. Sobell, Melodie Young. A series of critically challenging case scenarios in moderate to severe psoriasis: A Delphi consensus approach. Journal of the American Academy of Dermatology 2009; 61(1): S1 doi: 10.1016/j.jaad.2009.03.017
|
| 65 |
Frank Hoentjen, Atsushi Sakuraba, Stephen Hanauer. Update on the Management of Ulcerative Colitis. Current Gastroenterology Reports 2011; 13(5): 475 doi: 10.1007/s11894-011-0216-6
|
| 66 |
Shiv Kumar Sarin, Ashish Kumar, John A. Almeida, Yogesh Kumar Chawla, Sheung Tat Fan, Hitendra Garg, H. Janaka de Silva, Saeed Sadiq Hamid, Rajiv Jalan, Piyawat Komolmit, George K. Lau, Qing Liu, Kaushal Madan, Rosmawati Mohamed, Qin Ning, Salimur Rahman, Archana Rastogi, Stephen M. Riordan, Puja Sakhuja, Didier Samuel, Samir Shah, Barjesh Chander Sharma, Praveen Sharma, Yasuhiro Takikawa, Babu Ram Thapa, Chun-Tao Wai, Man-Fung Yuen. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology International 2009; 3(1): 269 doi: 10.1007/s12072-008-9106-x
|
| 67 |
Jason K. Hou, Fernando Velayos, Norah Terrault, Uma Mahadevan. Viral hepatitis and inflammatory bowel disease. Inflammatory Bowel Diseases 2010; 16(6): 925 doi: 10.1002/ibd.21284
|
| 68 |
Yiyi Chen, Zhexin Shao, Zhou Yin, Zhuxiu Jiang. Fibronectin predicts the outcome of acute-on-chronic hepatitis B liver failure. International Health 2015; 7(1): 67 doi: 10.1093/inthealth/ihu060
|
| 69 |
Jesús Sanz Sanz, Lucía Silva Fernández, José Luis Calleja Panero, Mónica Fernández-Castro, José Luis Andreu Sánchez. Infliximab en la espondilitis anquilosante asociada a infección crónica por el virus de la hepatitis B. Papel del tratamiento con lamivudina. Reumatología Clínica 2008; 4(4): 159 doi: 10.1016/S1699-258X(08)71826-6
|
| 70 |
Rosario Ibáñez Bosch. Tratamiento de situaciones clínicas difíciles en pacientes que presentan artritis reumatoide con hepatitis. Reumatología Clínica 2009; 5: 53 doi: 10.1016/j.reuma.2008.11.006
|
| 71 |
M Raphaelle Jean, Ann Weaver, Teresa Mastin-Diebold, Krista Kissinger, Emily A Smitherman, Leslie Favier, Lara Danziger-Isakov, Elizabeth Williams, Rebecca C Brady, Jennifer Huggins, Lee A Denson, Shehzad A Saeed, Pamela Morgan, Dana Michelle Hines Dykes. Improving a process to obtain hepatitis B serology among patients treated with infliximab at a large urban children’s hospital. BMJ Open Quality 2017; 6(2): e000092 doi: 10.1136/bmjoq-2017-000092
|
| 72 |
Tauseef Ali, Mohammad F. Madhoun, Michael Bronze, Laura Yun, David Shapiro. Viral Infections in Patients With Inflammatory Bowel Disease on Immunosuppressants. The American Journal of the Medical Sciences 2012; 343(3): 227 doi: 10.1097/MAJ.0b013e31821ff728
|
| 73 |
Eliza F. Chakravarty. Viral infection and reactivation in autoimmune disease. Arthritis & Rheumatism 2008; 58(10): 2949 doi: 10.1002/art.23883
|
| 74 |
Ruwaida Ben Musa, Anuhya Gampa, Sanjib Basu, Ali Keshavarzian, Garth Swanson, Michael Brown, Rana Abraham, Keith Bruninga, John Losurdo, Mark DeMeo, Sohrab Mobarhan, David Shapiro, Ece Mutlu. Hepatitis B vaccination in patients with inflammatory bowel disease. World Journal of Gastroenterology 2014; 20(41): 15358-15366 doi: 10.3748/wjg.v20.i41.15358
|
| 75 |
Nicola Petrosillo, Cecilia M. J. Drapeau. Crohn’s Disease. 2010; : 239 doi: 10.1007/978-88-470-1472-5_22
|
| 76 |
Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Ottavia Magnani, Francesco Puppo. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opinion on Drug Safety 2014; 13(5): 649 doi: 10.1517/14740338.2014.899579
|
| 77 |
Filomena Morisco, Fabiana Castiglione, Antonio Rispo, Tommaso Stroffolini, Roberto Vitale, Stefano Sansone, Rocco Granata, Ambrogio Orlando, Riccardo Marmo, Gabriele Riegler, Maurizio Vecchi, Livia Biancone, Nicola Caporaso. Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease. Digestive and Liver Disease 2011; 43: S40 doi: 10.1016/S1590-8658(10)60691-3
|
| 78 |
Matthew B. Carroll, Michael I. Bond. Use of Tumor Necrosis Factor-α Inhibitors in Patients with Chronic Hepatitis B Infection. Seminars in Arthritis and Rheumatism 2008; 38(3): 208 doi: 10.1016/j.semarthrit.2007.10.011
|
| 79 |
T.‐M. SCHERZER, K. STAUFER, G. NOVACEK, P. STEINDL‐MUNDA, S. SCHUMACHER, H. HOFER, P. FERENCI, H. VOGELSANG. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2008; 28(6): 742 doi: 10.1111/j.1365-2036.2008.03779.x
|
| 80 |
Hiroko Kuwabara, Akira Fukuda, Yasuhiro Tsuda, Yuro Shibayama. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clinical Rheumatology 2013; 32(S1): 47 doi: 10.1007/s10067-010-1438-y
|
| 81 |
Venessa Pattullo. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clinical and Molecular Hepatology 2016; 22(2): 219 doi: 10.3350/cmh.2016.0024
|
| 82 |
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow. Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study. Vaccines 2024; 12(4): 364 doi: 10.3390/vaccines12040364
|
| 83 |
Rotraut Mössner, Michael P. Schön, Kristian Reich. Tumor necrosis factor antagonists in the therapy of psoriasis. Clinics in Dermatology 2008; 26(5): 486 doi: 10.1016/j.clindermatol.2007.10.030
|
| 84 |
Gil Y. Melmed. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflammatory Bowel Diseases 2009; 15(9): 1410 doi: 10.1002/ibd.20943
|
| 85 |
Patrícia Andrade, João Santos‐Antunes, Susana Rodrigues, Susana Lopes, Guilherme Macedo. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. Journal of Gastroenterology and Hepatology 2015; 30(11): 1591 doi: 10.1111/jgh.13001
|
| 86 |
Byron P. Vaughn, Glen A. Doherty, Shiva Gautam, Alan C. Moss, Adam S. Cheifetz. Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. Inflammatory Bowel Diseases 2012; 18(6): 1057 doi: 10.1002/ibd.21824
|
| 87 |
Jonathan Moses, Naim Alkhouri, Angela Shannon, Kathy Raig, Rocio Lopez, Lara Danziger-Isakov, Ariel E Feldstein, Nizar N Zein, Robert Wyllie, Christine Carter-Kent. Hepatitis B Immunity and Response to Booster Vaccination in Children With Inflammatory Bowel Disease Treated With Infliximab. American Journal of Gastroenterology 2012; 107(1): 133 doi: 10.1038/ajg.2011.295
|
| 88 |
Yukitomo Urata, Ryoko Uesato, Dai Tanaka, Kenji Kowatari, Taisuke Nitobe, Yoshihide Nakamura, Shigeru Motomura. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 2011; 21(1): 16 doi: 10.3109/s10165-010-0337-z
|
| 89 |
Alfredo Papa, Carla Felice, Manuela Marzo, Gianluca Andrisani, Alessandro Armuzzi, Marcello Covino, Giammarco Mocci, Daniela Pugliese, Italo De Vitis, Antonio Gasbarrini, Gian Lodovico Rapaccini, Luisa Guidi. Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents. Journal of Crohn's and Colitis 2013; 7(2): 113 doi: 10.1016/j.crohns.2012.03.001
|
| 90 |
Nafiye Urganci, Derya Kalyoncu. Immunogenecity of Hepatitis A and B Vaccination in Pediatric Patients With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition 2013; 56(4): 412 doi: 10.1097/MPG.0b013e31827dd87d
|
| 91 |
Ziying Lei, Zhishuo Mo, Jianyun Zhu, Xiuqing Pang, Xingrong Zheng, Zhebin Wu, Ke Wang, Xinhua Li, Dongying Xie, Zhiliang Gao. Soluble ST2 Plasma Concentrations Predict Mortality in HBV-Related Acute-on-Chronic Liver Failure. Mediators of Inflammation 2015; 2015: 1 doi: 10.1155/2015/535938
|
| 92 |
Perry K Pratt, Nunes David, Horst C Weber, Frédéric F Little, Themistoklis Kourkoumpetis, Gregory J Patts, Janice Weinberg, Francis A Farraye. Antibody Response to Hepatitis B Virus Vaccine is Impaired in Patients With Inflammatory Bowel Disease on Infliximab Therapy. Inflammatory Bowel Diseases 2018; 24(2): 380 doi: 10.1093/ibd/izx001
|
| 93 |
J. P. Gisbert, L. Menchén, V. García‐Sánchez, I. Marín, J. R. Villagrasa, M. Chaparro. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2012; 35(12): 1379 doi: 10.1111/j.1365-2036.2012.05110.x
|
| 94 |
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich, Francesco Puppo. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Modern Rheumatology 2018; 28(3): 417 doi: 10.1080/14397595.2017.1366006
|
| 95 |
Takashi Ishige, Toshiaki Shimizu, Kenji Watanabe, Katsuhiro Arai, Koichi Kamei, Takahiro Kudo, Reiko Kunisaki, Daisuke Tokuhara, Makoto Naganuma, Tatsuki Mizuochi, Atsuko Murashima, Yuta Inoki, Naomi Iwata, Itaru Iwama, Sachi Koinuma, Hirotaka Shimizu, Keisuke Jimbo, Yugo Takaki, Shohei Takahashi, Yuki Cho, Ryusuke Nambu, Daisuke Nishida, Shin-ichiro Hagiwara, Norikatsu Hikita, Hiroki Fujikawa, Kenji Hosoi, Shuhei Hosomi, Yohei Mikami, Jun Miyoshi, Ryusuke Yagi, Yoko Yokoyama, Tadakazu Hisamatsu. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. Journal of Gastroenterology 2023; 58(2): 135 doi: 10.1007/s00535-022-01953-w
|
| 96 |
Yolima Cossio‐Gil, Xavier Martínez‐Gómez, Magda Campins‐Martí, José Ángel Rodrigo‐Pendás, Natalia Borruel‐Sainz, Francisco Rodríguez‐Frías, Francesc Casellas‐Jordà. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. Journal of Gastroenterology and Hepatology 2015; 30(1): 92 doi: 10.1111/jgh.12712
|
| 97 |
Carmelita Colbert, Arturo Chavarria, Charles Berkelhammer. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohnʼs disease. Inflammatory Bowel Diseases 2007; 13(11): 1453 doi: 10.1002/ibd.20216
|
| 98 |
Elisabetta Degasperi, Flavio Caprioli, Omar El Sherif, David Back, Massimo Colombo, Alessio Aghemo. Challenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection. Expert Review of Gastroenterology & Hepatology 2016; 10(12): 1373 doi: 10.1080/17474124.2016.1246181
|
| 99 |
Nigel W Crawford, Anthony G Catto-Smith, Mark R Oliver, Donald JS Cameron, Jim P Buttery. An australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterology 2011; 11(1) doi: 10.1186/1471-230X-11-87
|
| 100 |
Carme Loras, Cristina Saro, Ferràn Gonzalez-Huix, Miguel Mínguez, Olga Merino, Javier P Gisbert, Jesús Barrio, Antonio Bernal, Ana Gutiérrez, Marta Piqueras, Xavier Calvet, Montserrat Andreu, Agueda Abad, Daniel Ginard, Luis Bujanda, Julián Panés, Miquel Torres, Fernando Fernández-Bañares, Josep M Viver, Maria Esteve. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study. The American Journal of Gastroenterology 2009; 104(1): 57 doi: 10.1038/ajg.2008.4
|
| 101 |
Frank Hoentjen, Ad A van Bodegraven. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World Journal of Gastroenterology 2009; 15(17): 2067-2073 doi: 10.3748/wjg.15.2067
|
| 102 |
S. Domm, J. Cinatl, U. Mrowietz. The impact of treatment with tumour necrosis factor-α antagonists on the course of chronic viral infections: a review of the literature. British Journal of Dermatology 2008; 159(6): 1217 doi: 10.1111/j.1365-2133.2008.08851.x
|
| 103 |
J.-B. Chevaux, M.-A. Bigard, M. Bensenane, A. Oussalah, S. Jarlot, A. Belle, A. Nani, J.-P. Bronowicki, L. Peyrin-Biroulet. Inflammatory bowel disease and hepatitis B and C. Gastroentérologie Clinique et Biologique 2009; 33(12): 1082 doi: 10.1016/j.gcb.2009.03.021
|
| 104 |
Yves Poulin, Geneviève Thérien. Drug-Induced Hepatitis and Lupus during Infliximab Treatment for Psoriasis: Case Report and Literature Review. Journal of Cutaneous Medicine and Surgery 2010; 14(2): 100 doi: 10.2310/7750.2009.09007
|
| 105 |
R. Laurenti, F. Giovannangeli, E. Gubinelli, M. T. Viviano, A. Errico, L. Leoni, E. Ballanti, A. Migliore. Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients. Clinical and Developmental Immunology 2013; 2013: 1 doi: 10.1155/2013/410521
|
| 106 |
Yukitomo Urata, Ryoko Uesato, Dai Tanaka, Kenji Kowatari, Taisuke Nitobe, Yoshihide Nakamura, Shigeru Motomura. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Modern Rheumatology 2011; 21(1): 16 doi: 10.3109/s10165-010-0337-z
|
| 107 |
Jesús Sanz Sanz, Lucía Silva Fernández, José Luis Calleja Panero, Mónica Fernández-Castro, José Luis Andreu Sánchez. Infliximab in Ankylosing Spondylitis Associated With Chronic Hepatitis B Infection. Role of Lamivudine Therapy. Reumatología Clínica (English Edition) 2008; 4(4): 159 doi: 10.1016/S2173-5743(08)70180-1
|
| 108 |
William Huang, Kelly M. Cordoro, Sarah L. Taylor, Steven R. Feldman. To test or not to test? An evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis. Journal of the American Academy of Dermatology 2008; 58(6): 970 doi: 10.1016/j.jaad.2008.03.004
|
| 109 |
Clinton W. Enos, Ana Ormaza Vera, Abby S. Van Voorhees. Clinical Data on Laboratory Testing for Patients Taking Systemic Immunomodulatory Agents. JAMA Dermatology 2024; 160(3): 271 doi: 10.1001/jamadermatol.2023.5891
|
| 110 |
E. A. Kouroumalis. IBD 2007 — Achievements in Research and Clinical Practice. Falk Symposium 2008; 159: 60 doi: 10.1007/978-1-4020-6987-1_7
|
| 111 |
Robert Bissonnette, Vincent Ho, Richard G. Langley. Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis. Journal of Cutaneous Medicine and Surgery 2009; 13(5_suppl): S67 doi: 10.2310/7750.2009.00023
|